A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYH2051 Monotherapy in Patients With Advanced Solid Tumors or in Combination With Radiotherapy in Patients With Locally Advanced Head and Neck Cancer
Latest Information Update: 29 Oct 2023
At a glance
- Drugs SYH-2051 (Primary)
- Indications Head and neck cancer; Solid tumours
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 31 Aug 2023 New trial record